REGULATORY
Lilly’s Selpercatinib Clears Key Panel, in Line for September Approval
August 2, 2021
A key health ministry advisory panel on July 30 gave the thumbs-up to the approval of Eli Lilly Japan’s RET kinase inhibitor selpercatinib, known as Retevmo overseas, with the green-light putting it in line for…

LATEST

August 2, 2021
Daiichi Sankyo’s April-June sales soared 11.4% over a year ago on the back of strong performances from global products Lixiana (edoxaban) and Enhertu (trastuzumab deruxtecan), with the iron deficiency treatment Injectafer (ferric carboxymaltose) also lending…
August 2, 2021
Astellas Pharma saw its sales grow over 6% in the first quarter of FY2021, but its profits tumbled due to impairment losses incurred from the termination of development projects, including its peanut allergy vaccine ASP0892.In…
August 2, 2021
Takeda Pharmaceutical’s NEDD8-activating enzyme inhibitor pevonedistat cleared a key health ministry panel on July 30 for sakigake fast-track designation, opening the way for it to be the first drug to gain the status since the scheme earned full legal backing…
By Eric Persoff

Biopharmaceutical wholesalers in Japan play broader roles than their counterparts overseas. Beyond logistics and distribution, wholesalers perform a variety of tasks related to finance, safety, and commercialization. Such functions are typically cited as justification for various fees, rebates, and allowances…

By Yoshinori Sagehashi

With its first “off-year” drug price revision implemented this April, Japan has now wrapped up all the reform plans agreed upon by four state ministers in 2016 for pharmaceutical pricing. As the government has provided no further mid-term vision for…

The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…

By Yoshinori Sagehashi

Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…

Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…

Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…

NEWS CATEGORY

REGULATORY

BUSINESS

ORGANIZATION

ACADEMIA